[go: up one dir, main page]

AU4551499A - Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5-HT3 receptors - Google Patents

Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5-HT3 receptors

Info

Publication number
AU4551499A
AU4551499A AU45514/99A AU4551499A AU4551499A AU 4551499 A AU4551499 A AU 4551499A AU 45514/99 A AU45514/99 A AU 45514/99A AU 4551499 A AU4551499 A AU 4551499A AU 4551499 A AU4551499 A AU 4551499A
Authority
AU
Australia
Prior art keywords
agonists
antagonists
receptors
multivalent
partial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU45514/99A
Inventor
John H Griffin
Susan Meier-Davis
Guang Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innoviva Inc
Original Assignee
Advanced Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Medicine Inc filed Critical Advanced Medicine Inc
Publication of AU4551499A publication Critical patent/AU4551499A/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406Neurotransmitters
    • G01N33/942Serotonin, i.e. 5-hydroxy-tryptamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/30Psychoses; Psychiatry
    • G01N2800/301Anxiety or phobic disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/30Psychoses; Psychiatry
    • G01N2800/304Mood disorders, e.g. bipolar, depression

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU45514/99A 1998-06-08 1999-06-08 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5-HT3 receptors Abandoned AU4551499A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US8846698P 1998-06-08 1998-06-08
US60088466 1998-06-08
US9293898P 1998-07-15 1998-07-15
US60092938 1998-07-15
US12028299P 1999-02-16 1999-02-16
US60120282 1999-02-16
PCT/US1999/012768 WO1999064046A1 (en) 1998-06-08 1999-06-08 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5-ht3 receptors

Publications (1)

Publication Number Publication Date
AU4551499A true AU4551499A (en) 1999-12-30

Family

ID=27375973

Family Applications (1)

Application Number Title Priority Date Filing Date
AU45514/99A Abandoned AU4551499A (en) 1998-06-08 1999-06-08 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5-HT3 receptors

Country Status (4)

Country Link
EP (1) EP1085888A1 (en)
AU (1) AU4551499A (en)
CA (1) CA2321191A1 (en)
WO (1) WO1999064046A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003100091A1 (en) * 2002-05-24 2003-12-04 Epidauros Biotechnologie Ag Means and methods for improved treatment using 'setrones'
GB2398071B (en) * 2003-01-24 2006-06-07 Synthon Bv Process for making ondansetron and intermediate thereof
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8730691A (en) * 1990-09-28 1992-04-28 Neorx Corporation Polymeric carriers for release of covalently linked agents
AU2332497A (en) * 1996-03-19 1997-10-10 Salk Institute For Biological Studies, The (in vitro) methods for identifying modulators of members of the steroid/thyroid superfamily of receptors

Also Published As

Publication number Publication date
CA2321191A1 (en) 1999-12-16
WO1999064046A1 (en) 1999-12-16
EP1085888A1 (en) 2001-03-28
WO1999064046A8 (en) 2001-08-16
WO1999064046A9 (en) 2000-04-20

Similar Documents

Publication Publication Date Title
AU4426599A (en) Multivalent agonists, partial agonists, inverse agonists and antagonists of the D1 receptors
AU5265599A (en) Amine compounds, their production and their use as somatostatin receptor antagonists or agonists
AU1772300A (en) Glucagon antagonists/inverse agonists
PL366233A1 (en) Substituted pyridoindoles as serotonin agonists and antagonists
AU6391299A (en) Methods of identifying inverse agonists of the serotonin 2a receptor
GR3034514T3 (en) Benzonitriles and -fluorides as 5-HT agonists and antagonists
IL144673A0 (en) CRYSTAL STRUCTURE OF cPLA2, AND METHODS OF IDENTIFYING AGONISTS AND ANTAGONISTS USING SAME
AU2001243345A1 (en) 1983, 52881, 2398, 45449, 50289, and 52872, g protein-coupled receptors and uses therefor
AU4217299A (en) Pth1r and pth3r receptors, methods and uses thereof
AUPP380498A0 (en) Egf receptor agonists and antagonists
ZA200100978B (en) Muscarinic agonists and antagonists.
EP1023269A4 (en) Beta3-adrenoreceptor agonists, agonist compositions and methods of using
AU1100300A (en) Piperidyloxadiazoles as dopamine receptor antagonists
AU5861900A (en) Receptor agonists and antagonists
EP1137938A4 (en) Methods of screening for agonists and antagonists of the hdpxu17 receptor
AU4178497A (en) HTm4, methods of treatment and assays, agonists and antagonists
AU2002223528A1 (en) New n, n'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
AU6503900A (en) Chemokine receptor antagonists and methods of use therefor
AU4551499A (en) Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5-HT3 receptors
AU6389900A (en) Chemokine receptor antagonists and methods of use therefor
AU5297299A (en) Cytokine and cytokine receptor, agonist, antagonist and/or antibody combination for therapeutic use
AU2003246937A1 (en) Methods to identify true antagonists and inverse agonists of the cannabinoid receptor
AU6499100A (en) Chemokine receptor antagonists and methods of use therefor
AU5234899A (en) Alpha 1a adrenergic receptor antagonists
SI1237553T1 (en) The combination of a serotonin reuptake inhibitor and a 5-ht 2c? antagonist, inverse agonist or partial agonist

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase